Article
Immunology
Cristina Cocco, Elias Manca, Giulia Corda, Maria Maddalena Angioni, Barbara Noli, Mattia Congia, Francesco Loy, Michela Isola, Elisabetta Chessa, Alberto Floris, Lorena Lorefice, Luca Saba, Alessandro Mathieu, Gian Luca Ferri, Alberto Cauli, Matteo Piga
Summary: Brain-reactive autoantibodies are found in patients with SLE and NPSLE, with higher frequency and titers observed in NPSLE patients. The target antigens of these autoantibodies are still undetermined, but they likely include β2GPI.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Medicine, General & Internal
Jiangbiao Xiong, Gang Wang, Tian Xu, Ren Liu, Shujiao Yu, Yan Wang, Rui Wu
Summary: This study aimed to explore the risk factors for osteonecrosis in patients with SLE. The results showed that the score of ECLAM at SLE onset, a cumulative dose of prednisone above 10 g, and positive anti-RNP antibodies were significantly associated with osteonecrosis in SLE. It was also found that anti-RNP antibodies might be a novel predictor for osteonecrosis in SLE patients.
FRONTIERS IN MEDICINE
(2022)
Article
Rheumatology
May Yee Choi, Ann Elaine Clarke, Murray Urowitz, John Hanly, Yvan St-Pierre, Caroline Gordon, Sang-Cheol Bae, Juanita Romero-Diaz, Jorge Sanchez-Guerrero, Sasha Bernatsky, Daniel J. Wallace, David Isenberg, Anisur Rahman, Joan T. Merrill, Paul R. Fortin, Dafna D. Gladman, Ian N. Bruce, Michelle Petri, Ellen M. Ginzler, Mary Anne Dooley, Rosalind Ramsey-Goldman, Susan Manzi, Andreas Jonsen, Graciela S. Alarcon, Ronald F. van Vollenhoven, Cynthia Aranow, Meggan Mackay, Guillermo Ruiz-Irastorza, Sam Lim, Murat Inanc, Ken Kalunian, Soren Jacobsen, Christine Peschken, Diane L. Kamen, Anca Askanase, Jill P. Buyon, Karen H. Costenbader, Marvin J. Fritzler
Summary: In a longitudinal analysis of a large international incident SLE cohort, three ANA assays demonstrated high positivity rates and commutability. However, over a 5-year follow-up, there was a modest variation in ANA assay performance.
ANNALS OF THE RHEUMATIC DISEASES
(2022)
Review
Medicine, Research & Experimental
Farid Ghorbaninezhad, Patrizia Leone, Hajar Alemohammad, Basira Najafzadeh, Niloufar Nourbakhsh, Marcella Prete, Eleonora Malerba, Hossein Saeedi, Neda Tabrizi, Vito Racanelli, Behzad Baradaran
Summary: This study reviews the dual role of tumor necrosis factor-alpha (TNF-alpha) in systemic lupus erythematosus (SLE), as well as the efficacy and safety of anti-TNF-alpha therapies in SLE.
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
(2022)
Article
Rheumatology
May Yee Choi, Irene Chen, Ann Elaine Clarke, Marvin J. Fritzler, Katherine A. Buhler, Murray Urowitz, John Hanly, Yvan St-Pierre, Caroline Gordon, Sang-Cheol Bae, Juanita Romero-Diaz, Jorge Sanchez-Guerrero, Sasha Bernatsky, Daniel J. Wallace, David Alan Isenberg, Anisur Rahman, Joan T. Merrill, Paul R. Fortin, Dafna D. Gladman, Ian N. Bruce, Michelle Petri, Ellen M. Ginzler, Mary Anne Dooley, Rosalind Ramsey-Goldman, Susan Manzi, Andreas Jonsen, Graciela S. Alarcon, Ronald F. van Vollenhoven, Cynthia Aranow, Meggan Mackay, Guillermo Ruiz-Irastorza, Sam Lim, Murat Inanc, Kenneth Kalunian, Soren Jacobsen, Christine Peschken, Diane L. Kamen, Anca Askanase, Jill P. Buyon, David Sontag, Karen H. Costenbader
Summary: A novel longitudinal clustering technique was used to analyze comprehensive autoantibody data from a large, well-characterised, multinational inception SLE cohort, in order to determine predictive profiles of clinical outcomes.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Review
Rheumatology
Mary K. Crow
Summary: Research has identified type I interferon (IFN-I) and autoantibodies targeting nucleic acids and nucleic acid-binding proteins as fundamental contributors to the pathogenesis of systemic lupus erythematosus (SLE). This review summarizes recent genetic analyses of SLE patients and current studies on innate and adaptive immune function, which contribute to sustained IFN-I pathway activation, immune activation, autoantibody production, inflammatory mediator generation, and tissue damage. The goal of these studies is to understand disease mechanisms, identify therapeutic targets, and develop better treatments for patients.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Rheumatology
Christina Adamichou, Irini Genitsaridi, Dionysis Nikolopoulos, Myrto Nikoloudaki, Argyro Repa, Alessandra Bortoluzzi, Antonis Fanouriakis, Prodromos Sidiropoulos, Dimitrios T. Boumpas, George K. Bertsias
Summary: A machine learning algorithm was developed to assist in the diagnosis of SLE by analyzing patient data sets, leading to improved diagnostic and treatment outcomes.
ANNALS OF THE RHEUMATIC DISEASES
(2021)
Review
Immunology
Gabriela Guzman-Martinez, Concepcion Maranon
Summary: Patients with systemic lupus erythematosus (SLE) have an increased risk of cardiovascular disease (CVD), which is becoming one of the most relevant complications and a significant factor causing morbidity and mortality in SLE. Immune constituents, including specific circulating cell populations, autoantibodies, and inflammatory mediators, play a role in the pathogenesis of atherosclerosis and endothelial damage in SLE patients. This review summarizes the presentation of CVD in SLE, the role of autoimmune responses in inducing atherogenesis, endothelial impairment, and cardiac disease, and discusses the utility of immune mediators as early CVD biomarkers and targets for clinical intervention in SLE patients.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Immunology
Jiaxuan Chen, Shuzhen Liao, Huimin Zhou, Lawei Yang, Fengbiao Guo, Shuxian Chen, Aifen Li, Quanren Pan, Chen Yang, Hua-feng Liu, Qingjun Pan
Summary: Animal models play a crucial role in understanding human diseases, but they cannot fully simulate the occurrence and progression of diseases due to genetic and disease-specific differences. Humanized immune system mice, developed from immunodeficient mice, provide a partial reconstruction of the human immune system and mimic the in vivo microenvironment. However, there are challenges in developing humanized mice models for systemic lupus erythematosus (SLE), including improving immune response reconstruction efficiency, extending observation period, and improving model development and utilization.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Cell Biology
M. Constanza Baroni Pietto, Paola R. Lev, Ana C. Glembotsky, Cecilia P. Marin Oyarzun, Graciela Gomez, Victoria Collado, Cecilia Pisoni, Ramiro A. Gomez, Matias Grodzielski, Jacqueline Gonzalez, Karina Marino, Paula G. Heller, Nora P. Goette, Rosana F. Marta
Summary: The study found that systemic lupus erythematosus (SLE) patients with thrombocytopenia have abnormalities in platelet clearance and production, mainly due to apoptosis and desialylation leading to low platelet count. These abnormalities are more frequently observed in patients with thrombocytopenia and active disease.
Article
Medicine, General & Internal
Yen-Fu Chen, Ao-Ho Hsieh, Lian-Chin Wang, Kuang-Hui Yu, Chang-Fu Kuo
Summary: The research indicates a strong association between CMV infection and the development of SLE, with a high prevalence of anti-CMV and anti-TAF9 IgG in SLE patients. Elevated anti-CMVpp65 immunity in SLE appears to cross-react with TAF9 and dsDNA, potentially contributing to clinical manifestations such as proteinuria and low hemoglobin levels.
JOURNAL OF CLINICAL MEDICINE
(2021)
Editorial Material
Cell Biology
Simon Fillatreau
Summary: The study reveals that autoantibodies in systemic lupus erythematosus (SLE) can have a protective role by neutralizing type I interferons (IFNs) and restraining the activation of pathogenic B cells.
CELL REPORTS MEDICINE
(2023)
Article
Cell Biology
Jin Kyun Park, Ye Ji Lee, Ji Soo Park, Eun Bong Lee, Yeong Wook Song
Summary: In patients with SLE, CD47 expression is upregulated in monocytes and correlates with disease activity. CD47 contributes to augmented inflammatory responses in SLE, suggesting that targeting CD47 may be a novel treatment approach for SLE.
Review
Rheumatology
Eduardo Gomez-Banuelos, Andrea Fava, Felipe Andrade
Summary: Autoantibodies play a crucial role in systemic lupus erythematosus (SLE) as they cause tissue damage. They provide information about disease susceptibility, clinical course, outcomes, and the cause of SLE. However, identifying pathogenic autoantibodies in SLE is still challenging. This review summarizes recent advances in the field of autoantibodies in SLE.
CURRENT OPINION IN RHEUMATOLOGY
(2023)
Review
Urology & Nephrology
Na Kang, Xiaohang Liu, Xujie You, Wenbo Sun, Kabeer Haneef, Xiaolin Sun, Wanli Liu
Summary: Aberrant B-cell activation is closely linked to the pathogenesis of SLE, with dysregulations of B-cell receptor (BCR), toll-like receptor (TLR), and B-cell activating factor receptor (BAFF-R) pathways being common factors. Targeting these aberrant signaling pathways has shown promise in alleviating clinical symptoms of SLE, emphasizing the importance of identifying new drug targets for future therapeutic strategies.
